Pyxis Oncology (PYXS) vs Sutro Biopharma (STRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Sutro Biopharma (STRO) has outperformed Pyxis Oncology (PYXS) over the past year, gaining 74.5% versus a loss of 21.2%. Over five years, PYXS leads with a -82.9% price change compared with -92.3% for STRO. Sutro Biopharma is the larger company by market cap ($243.1 million vs $240.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PYXS | STRO |
|---|---|---|
| Share price | $2.01 | $14.66 |
| Market cap | $240.11M | $243.08M |
| 1-day change | -0.50% | +1.45% |
| YTD return | +74.78% | +26.71% |
| 1-year return | -21.18% | +74.52% |
| 5-year return | -82.92% | -92.28% |
| EPS (TTM) | $-1.40 | $-17.28 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.55 | $43.85 |
| 52-week low | $1.03 | $7.15 |
| Distance from 52-week high | -63.78% | -66.57% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +331.34% | +222.17% |
| Average volume | 1.26M | 289.73K |
| Shares outstanding | 119.46M | 16.58M |
| Employees | 56 | 128 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STRO has outperformed PYXS by 95.7 percentage points over the past year.
About Pyxis Oncology
PYXS stock →Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Healthcare · Biotechnology · 56 employees
About Sutro Biopharma
STRO stock →Sutro Biopharma, Inc. operates as an oncology company.
Healthcare · Biotechnology · 128 employees
PYXS vs STRO FAQ
Which is bigger, Pyxis Oncology or Sutro Biopharma?
Sutro Biopharma (STRO) is larger, with a market capitalization of $243.08M compared with $240.11M for Pyxis Oncology (PYXS).
Which stock has performed better over the past year, PYXS or STRO?
STRO returned +74.52% over the past 12 months, compared with -21.18% for PYXS (price return, excluding dividends). Past performance does not predict future results.
Are Pyxis Oncology and Sutro Biopharma in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.